Repligen(美国)

Repligen Corporation

美国RepligenCorporationwww.repligen.comRepligen公司成立于1981年在特拉华州和在纳斯达克上市，交易代码RGEN。该公司的重点是对神经系统疾病的新疗法。发展计划，目前正在对胰腺进行磁共振成像等领域，躁郁症，弗里德的共济失调和脊髓性肌萎缩。此外，Repligen是世界上重组蛋白A的供应商的利润来自这有助于支持我们的临床开发项目。RepligenCorpora tionwasincorporatedin1981inDelawareandistradedontheNASDAQunderthesymbolRGEN.TheCompanyisfocusedonthedevelopmentofnoveltherapeuticsforneurologicaldisorders.DevelopmentprogramsarecurrentlybeingconductedintheareasofpancreaticMRIimaging,bipolardisorder,Friedreich'sataxiaandspinalmuscularatrophy.Inaddition,Repligenistheworld'sleadingsupplierofrecombinantProteinA,theprofitsfromwhichhelptosupportourclinicaldevelopmentprograms.RepligenhasalsosecuredasourceofrevenuethroughthesuccessfullicensingofCTLA4-Ig,andreceivesroyaltiesfromBristol-MyersSquibbbasedontheirU.S.salesofOrencia®forrheumatoidarthritis.TheCompanyislocatedinWaltham,Massachusettsandcurrently